BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37899948)

  • 1. Treatment of Cutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.
    Wozniak B; Bove T; Zawada T; Calik J
    Case Rep Dermatol; 2023; 15(1):194-201. PubMed ID: 37899948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.
    Oliveira LB; Geller M; Cunha KS; Santos A; Bernacchi A; Rubenstein AE; Takirambudde S; Mezitis S; de Almeida Ito Brum C; Darrigo LG; Ribeiro MG
    Heliyon; 2021 Mar; 7(3):e06518. PubMed ID: 33817379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey.
    Guiraud M; Bouroubi A; Beauchamp R; Bocquet A; Grégoire JM; Rauly-Lestienne I; Blanco I; Wolkenstein P; Schmitt AM
    Orphanet J Rare Dis; 2019 Dec; 14(1):286. PubMed ID: 31801570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous neurofibromas: Current clinical and pathologic issues.
    Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
    Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
    Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
    Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
    Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
    Nguyen HTL; Kohl E; Bade J; Eng SE; Tosevska A; Al Shihabi A; Tebon PJ; Hong JJ; Dry S; Boutros PC; Panossian A; Gosline SJC; Soragni A
    Cell Rep Methods; 2024 May; 4(5):100772. PubMed ID: 38744290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cutaneous neurofibroma: current therapy and future directions.
    Chamseddin BH; Le LQ
    Neurooncol Adv; 2020 Jul; 2(Suppl 1):i107-i116. PubMed ID: 32642736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment and progress of cutaneous neurofibroma].
    Zhu B; Wei C; Wang W; Gu B; Li Q; Wang Z
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2022 Sep; 36(9):1064-1071. PubMed ID: 36111466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
    Grit JL; Turner L; Essenburg CJ; Gallik KL; Dischinger PS; Shurlow ND; Pate MJ; Graveel CR; Steensma MR
    J Invest Dermatol; 2024 Feb; ():. PubMed ID: 38395106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creating a comprehensive research strategy for cutaneous neurofibromas.
    Blakeley JO; Wolkenstein P; Widemann BC; Lee J; Le LQ; Jackson R; Stathis M; Verma SK
    Neurology; 2018 Jul; 91(2 Suppl 1):S1-S4. PubMed ID: 29987129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.
    Richey P; Funk M; Sakamoto F; Plotkin S; Ly I; Jordan J; Muzikansky A; Roberts J; Farinelli W; Levin Y; Garibyan L; Blakeley JO; Anderson RR
    J Am Acad Dermatol; 2024 Apr; 90(4):767-774. PubMed ID: 38086517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
    Peltonen S; Jannic A; Wolkenstein P
    Eur J Med Genet; 2022 Jan; 65(1):104386. PubMed ID: 34768015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.
    Fertitta L; Bergqvist C; Armand ML; Moryousef S; Ferkal S; Jannic A; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1359-1366. PubMed ID: 35412677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.
    Rice FL; Houk G; Wymer JP; Gosline SJC; Guinney J; Wu J; Ratner N; Jankowski MP; La Rosa S; Dockum M; Storey JR; Carroll SL; Albrecht PJ; Riccardi VM
    PLoS One; 2019; 14(5):e0216527. PubMed ID: 31107888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials.
    Thalheimer RD; Merker VL; Ly KI; Champlain A; Sawaya J; Askenazi NL; Herr HP; Da JLW; Jordan JT; Muzikansky A; Pearce EM; Sakamoto FH; Blakeley JO; Anderson RR; Plotkin SR;
    Neurology; 2021 Aug; 97(7 Suppl 1):S32-S41. PubMed ID: 34230197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
    Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
    J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous neurofibromas in the genomics era: current understanding and open questions.
    Allaway RJ; Gosline SJC; La Rosa S; Knight P; Bakker A; Guinney J; Le LQ
    Br J Cancer; 2018 Jun; 118(12):1539-1548. PubMed ID: 29695767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
    Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
    Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities.
    Brosseau JP; Pichard DC; Legius EH; Wolkenstein P; Lavker RM; Blakeley JO; Riccardi VM; Verma SK; Brownell I; Le LQ
    Neurology; 2018 Jul; 91(2 Suppl 1):S14-S20. PubMed ID: 29987131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.